BioSpace News Archive

AIM ImmunoTech Inc. (NYSE American: AIM) announced today that the post-COVID-19 “Long Hauler” portion of the active AMP-511 Expanded Access Program (EAP) protocol received approval from the Institutional Review Board (IRB) for a public notification of potential patient enrollment. Eligible patients enrolled in the trial receive treatment with AIM’s flagship pipeline drug Ampligen. AIM announced in October that the myalgic encephalomyelitis/c

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI) , a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announces that on December 24, 2020, the Company received written notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has cured the bid price deficiency and has regained full compliance with all applicable cr

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to announce that the last patient from the Phase 2b part of its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19, has now completed treatment as well as the required two-week follow up. The Company announced positive tren

BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), a leading life sciences company specializing in perinatal tissue allografts for use in regenerative therapies, today announced that it has filed its quarterly reports for 2020 to become current with OTC Markets. BioStem’s Chief Executive Officer, Jason Matuszewski, commented, “The filing of our 2020 quarterly reports not only marks a key milestone for BioStem, but al

Soterix Medical Inc. , the global leader in non-invasive stimulation and synergistic brain imaging technologies, is pleased to report expanded clinical trials of its proprietary neuromodulation technologies for Alzheimer’s disease and Mild Cognitive Impairment. Adults over age 65 represent the fastest growing population in the US. Dec

As the resurgence of COVID-19 activity continues in Canada , we are tracking a range of epidemiological indicators to monitor where the disease is most active, where it is spreading and how it is impacting the health of Canadians and public health, laboratory and healthcare capacity. The following is the latest summary on national numbers

UPDATE: December 24, 2020 – Additional lots of GUM Paroex being recalled because this product may be contaminated with the bacteria Burkholderia lata.

Vaccines destined for the Canadian North will have travelled more than 10,000 kilometers to reach vaccination centres

MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended October 31, 2020. Profit and Loss Highlights Revenue: The Company recorded revenues in Q1 FY2021 of $1,602,823 compared to $89,132 in Q1 FY2020. The increase in revenue was due to the Company’s revenues generated from sales of the REVEALCOVID-19 TM Total Antibody Test and associated products and services. Gross Profit: The Company rec

Peer-reviewed Phase 1 data shows INO-4800 to be immunogenic in 100% of subjects, inducing neutralizing antibody and/or T cell responses INO-4800 demonstrates favorable safety and tolerability, with no serious adverse events reported Offers best-in-class thermostability, including a five-year projected shelf life at normal refrigeration temperature and no frozen transport or storage requirements